Adding Pembrolizumab to Chemotherapy Results in Improved PFS and OS in Patients with Advanced and Recurrent Cervical Cancer Regardless of Bevacizumab Use By Ogkologos - November 25, 2024 920 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the subgroup analysis of the KEYNOTE-826 study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Announces 2026 Society Award Recipients Honouring Excellence in Cancer Research, Care and Leadership Adjuvant Olaparib Continues to Improve Multiple Outcomes in Patients with Germline BRCA1/2-associated High-Risk HER2-negative EBC EMA Recommends Refusing the Marketing Authorisation for Copper (64Cu) Oxodotreotide MOST POPULAR Should People Over Age 75 Be Screened for Colorectal Cancer? June 15, 2021 Undetectable MRD and Extended PFS More Common with MRD-guided Ibrutinib-Venetoclax than... October 13, 2025 Study Confirms Dinutuximab Extends Life for Children with High-Risk Neuroblastoma September 6, 2022 Breaking News: Supreme Court Upholds the Affordable Care Act June 17, 2021 Load more HOT NEWS Reflections from the World Cancer Congress Study presents an AI-guided approach to target cancer antigens Hockey Fan Dubbed Hero After Saving Equipment Manager’s Life Clinical Trials in Genitourinary Cancers: MAGNITUDE, PROOF 302, and CYTOSHRINK
